Glucose-lowering medications have been the mainstay of managing type 2 diabetes for 20 years. But a recent polemic between diabetes organisations has prompted an examination of specific targets for blood sugar in different patients. The podcast also summarises the use of new drug classes that don’t just lower blood glucose but appear to provide cardiovascular benefits directly in sicker patients.
Guests: Professor Sophia Zoungas FRACP (Monash Health; Board Director, Diabetes Australia; Clinical Director, National Association of Diabetes Centres); Dr Paul Drury FRACP (Clinical Advisor in Diabetes, Ministry of Health; University of Auckland)
Create your
podcast in
minutes
It is Free